Tue, Dec 23, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Alternative Market Briefing

Axioma launches multi-asset class risk product

Thursday, October 24, 2013

amb
Sebastian Ceria
Bailey McCann, Opalesque New York:

Axioma a provider of equity risk management and portfolio products is moving into the multi-asset class risk analytics market with Axioma Risk. The new solution was launched yesterday at an event in New York City. The risk management platform is designed to move the company from equity risk management into a more comprehensive set of offerings.

"This is a watershed initiative for Axioma," said Sebastian Ceria, PhD, Axioma’s founder and Chief Executive Officer. The product is designed to be a risk-management platform for middle-to-front office users.

Ian Webster, Axioma’s Managing Director Europe, noted that the offering comes as funds and investors have moved toward multi-asset class investing as part of the new normal. Managers and investors alike have had difficulty relying on traditional portfolio construction techniques to realize the same returns they once were, but the move to more diversified investments also adds significantly to the risk profile of a given portfolio.

The simulation-based analytics utilize Axioma’s Robust Factor Models, which are fully integrated into the platform. During the event Ceria explained that the development team for the product is a mix of company insiders and industry experts that have become part of Axioma through strategic acquisitions.

Users of the product will be able to use information from one market in a model to estimate likely changes in another, and understand how v......................

To view our full article Click here

Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for